BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li H, Qin Y, Cui Y, Chen H, Hao X, Li Q. Analysis of the surgical outcome and prognostic factors for hilar cholangiocarcinoma: a Chinese experience. Dig Surg 2011;28:226-31. [PMID: 21540611 DOI: 10.1159/000327361] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Elshami M, Hue JJ, Ahmed FA, Kakish H, Hoehn RS, Rothermel LD, Hardacre JM, Ammori JB, Winter JM, Ocuin LM. Defining Facility Volume Threshold for Optimization of Short- and Long-Term Outcomes in Patients Undergoing Resection of Perihilar Cholangiocarcinoma. J Gastrointest Surg 2022. [PMID: 36138311 DOI: 10.1007/s11605-022-05465-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Watanabe J, Miki A, Sakuma Y, Shimodaira K, Aoki Y, Meguro Y, Morishima K, Endo K, Sasanuma H, Lefor AK, Teratani T, Fukushima N, Kitayama J, Sata N. Preoperative Osteopenia Is Associated with Significantly Shorter Survival in Patients with Perihilar Cholangiocarcinoma. Cancers (Basel) 2022;14:2213. [PMID: 35565342 DOI: 10.3390/cancers14092213] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Lee TH. Treatment of Malignant Hilar Strictures. Gastrointestinal and Pancreatico-Biliary Diseases: Advanced Diagnostic and Therapeutic Endoscopy 2022. [DOI: 10.1007/978-3-030-56993-8_81] [Reference Citation Analysis]
4 Zhang XF, Zhang N, Tsilimigras DI, Weber SM, Poultsides G, Hatzaras I, Fields RC, He J, Scoggins C, Idrees K, Shen P, Maithel SK, Pawlik TM. Surgical Strategies for Bismuth Type I and II Hilar Cholangiocarcinoma: Impact on Long-Term Outcomes. J Gastrointest Surg 2021;25:3084-91. [PMID: 34131864 DOI: 10.1007/s11605-021-05049-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Liang L, Li C, Jia HD, Diao YK, Xing H, Pawlik TM, Lau WY, Shen F, Huang DS, Zhang CW, Yang T. Prognostic factors of resectable perihilar cholangiocarcinoma: a systematic review and meta-analysis of high-quality studies. Ther Adv Gastrointest Endosc 2021;14:2631774521993065. [PMID: 33629062 DOI: 10.1177/2631774521993065] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Zhao J, Zhang W, Zhang J, Chen YT, Ma WJ, Liu SY, Li FY, Song B. Independent Risk Factors of Early Recurrence After Curative Resection for Perihilar Cholangiocarcinoma: Adjuvant Chemotherapy May Be Beneficial in Early Recurrence Subgroup. Cancer Manag Res 2020;12:13111-23. [PMID: 33376403 DOI: 10.2147/CMAR.S289094] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Jingdong L, Yongfu X, Yang G, Jian X, Xujian H, Jianhua L, Wenxing Z, Renyi Q, Xinming Y, Shuguo Z, Xiao L, Bin P, Qifan Z, Dewei L, Zhao-Hui T. Minimally invasive surgery for hilar cholangiocarcinoma: a multicenter retrospective analysis of 158 patients. Surg Endosc 2020. [PMID: 33258033 DOI: 10.1007/s00464-020-08161-8] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Hand F, Hoti E. Contemporary role of liver transplantation for the treatment of cholangiocarcinoma.Expert Rev Gastroenterol Hepatol. 2020;14:475-481. [PMID: 32401554 DOI: 10.1080/17474124.2020.1765771] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
9 Lee TH. Treatment of Malignant Hilar Strictures. Gastrointestinal and Pancreatico-Biliary Diseases: Advanced Diagnostic and Therapeutic Endoscopy 2020. [DOI: 10.1007/978-3-030-29964-4_81-1] [Reference Citation Analysis]
10 Vedenin Y, Zyubina E, Kondakov V, Davydova O. Percutaneous transhepatic catheter-directed biopsy for proximal cholangiocarcinoma. Oper khir 2020;4:4. [DOI: 10.17116/operhirurg202040114] [Reference Citation Analysis]
11 Bird NTE, Manu N, Quinn L, Needham A, Jones R, Fenwick S, Poston G, Palmer D, Malik H. Evaluation of the utility of prognostic models for patients with resected hilar cholangiocarcinoma. HPB (Oxford) 2019;21:1376-84. [PMID: 31078423 DOI: 10.1016/j.hpb.2019.02.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Kovalenko YA, Zharikov YO, Kukeev IA, Vishnevsky VA, Chzhao AV. [Predictors of outcomes in surgery for hilar cholangiocarcinoma]. Khirurgiia (Mosk) 2018;:5-11. [PMID: 30531729 DOI: 10.17116/hirurgia20181015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
13 Capobianco I, Rolinger J, Nadalin S. Resection for Klatskin tumors: technical complexities and results. Transl Gastroenterol Hepatol. 2018;3:69. [PMID: 30363698 DOI: 10.21037/tgh.2018.09.01] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
14 Tang Z, Yang Y, Zhao Z, Wei K, Meng W, Li X. The clinicopathological factors associated with prognosis of patients with resectable perihilar cholangiocarcinoma: A systematic review and meta-analysis. Medicine (Baltimore) 2018;97:e11999. [PMID: 30142840 DOI: 10.1097/MD.0000000000011999] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 5.6] [Reference Citation Analysis]
15 Bird NTE, McKenna A, Dodd J, Poston G, Jones R, Malik H. Meta-analysis of prognostic factors for overall survival in patients with resected hilar cholangiocarcinoma. Br J Surg. 2018;105:1408-1416. [PMID: 29999515 DOI: 10.1002/bjs.10921] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 5.8] [Reference Citation Analysis]
16 Fisher AV, Ronnekleiv-kelly SM. Surgical Management of Hilar Cholangiocarcinoma. Curr Surg Rep 2018;6. [DOI: 10.1007/s40137-018-0210-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
17 Pinotti E, Sandini M, Famularo S, Tamini N, Romano F, Gianotti L. Resection of the caudate lobe for the treatment of hilar cholangiocarcinoma. Minerva Chir 2019;74:348-58. [PMID: 29658674 DOI: 10.23736/S0026-4733.18.07498-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
18 Wang JK, Hu HJ, Shrestha A, Ma WJ, Yang Q, Liu F, Cheng NS, Li FY. Can preoperative and postoperative CA19-9 levels predict survival and early recurrence in patients with resectable hilar cholangiocarcinoma? Oncotarget 2017;8:45335-44. [PMID: 28484084 DOI: 10.18632/oncotarget.17336] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
19 Yang Y, Zhou Z, Liu R, Chen L, Xiang H, Chen N. Application of 3D visualization and 3D printing technology on ERCP for patients with hilar cholangiocarcinoma. Exp Ther Med 2018;15:3259-64. [PMID: 29545843 DOI: 10.3892/etm.2018.5831] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
20 Maruyama H, Tominaga K, Kato K, Sugimori S, Shiba M, Watanabe T, Fujiwara Y. Safety and efficacy of transpapillary bridged bilateral side-by-side stenting for unresectable malignant hilar biliary obstruction. Hepatobiliary Pancreat Dis Int 2017;16:659-61. [PMID: 29291787 DOI: 10.1016/S1499-3872(17)60072-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
21 Hu HJ, Zhou RX, Shrestha A, Tan YQ, Ma WJ, Yang Q, Lu J, Wang JK, Zhou Y, Li FY. Relationship of tumor size with pathological and prognostic factors for hilar cholangiocarcinoma. Oncotarget 2017;8:105011-9. [PMID: 29285229 DOI: 10.18632/oncotarget.22054] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
22 Schoellhammer HF, Fong Y, Singh G. Extrahepatic bile duct tumors. Blumgart's Surgery of the Liver, Biliary Tract and Pancreas, 2-Volume Set 2017. [DOI: 10.1016/b978-0-323-34062-5.00051-0] [Reference Citation Analysis]
23 Lehrke HD, Heimbach JK, Wu TT, Jenkins SM, Gores GJ, Rosen CB, Mounajjed T. Prognostic Significance of the Histologic Response of Perihilar Cholangiocarcinoma to Preoperative Neoadjuvant Chemoradiation in Liver Explants. Am J Surg Pathol. 2016;40:510-518. [PMID: 26752544 DOI: 10.1097/pas.0000000000000588] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
24 Hu HJ, Mao H, Tan YQ, Shrestha A, Ma WJ, Yang Q, Wang JK, Cheng NS, Li FY. Clinical value of preoperative serum CA 19-9 and CA 125 levels in predicting the resectability of hilar cholangiocarcinoma. Springerplus. 2016;5:551. [PMID: 27190750 DOI: 10.1186/s40064-016-2181-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
25 Mantel HT, Westerkamp AC, Sieders E, Peeters PM, de Jong KP, Boer MT, de Kleine RH, Gouw AS, Porte RJ. Intraoperative frozen section analysis of the proximal bile ducts in hilar cholangiocarcinoma is of limited value. Cancer Med 2016;5:1373-80. [PMID: 27062713 DOI: 10.1002/cam4.693] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
26 Hu HJ, Mao H, Shrestha A, Tan YQ, Ma WJ, Yang Q, Wang JK, Cheng NS, Li FY. Prognostic factors and long-term outcomes of hilar cholangiocarcinoma: A single-institution experience in China. World J Gastroenterol 2016; 22(8): 2601-2610 [PMID: 26937148 DOI: 10.3748/wjg.v22.i8.2601] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 47] [Article Influence: 6.1] [Reference Citation Analysis]
27 Akamatsu N, Sugawara Y, Kokudo N. The Assessment of Ductal Margin in Curative-Intent Surgery for Perihilar Cholangiocarcinoma. Difficult Decisions in Surgery: An Evidence-Based Approach 2016. [DOI: 10.1007/978-3-319-27365-5_31] [Reference Citation Analysis]
28 Gulamhusein AF, Sanchez W. Liver transplantation in the management of perihilar cholangiocarcinoma. Hepat Oncol 2015;2:409-21. [PMID: 30191020 DOI: 10.2217/hep.15.30] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
29 Mantel HT, Wiggers JK, Verheij J, Doff JJ, Sieders E, van Gulik TM, Gouw AS, Porte RJ. Lymph Node Micrometastases are Associated with Worse Survival in Patients with Otherwise Node-Negative Hilar Cholangiocarcinoma. Ann Surg Oncol. 2015;22 Suppl 3:S1107-S1115. [PMID: 26178761 DOI: 10.1245/s10434-015-4723-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
30 Xiang S, Lau WY, Chen XP. Hilar cholangiocarcinoma: controversies on the extent of surgical resection aiming at cure. Int J Colorectal Dis 2015;30:159-71. [PMID: 25376337 DOI: 10.1007/s00384-014-2063-z] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 4.5] [Reference Citation Analysis]
31 Lee TH, Moon JH, Park SH. Bilateral metallic stenting in malignant hilar obstruction. Clin Endosc. 2014;47:440-446. [PMID: 25325005 DOI: 10.5946/ce.2014.47.5.440] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
32 Goenka MK, Goenka U. Palliation: Hilar cholangiocarcinoma. World J Hepatol 2014; 6(8): 559-569 [PMID: 25232449 DOI: 10.4254/wjh.v6.i8.559] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
33 Yang H, Zhou J, Wei X, Wang F, Zhao H, Li E. Survival outcomes and progonostic factors of extrahepatic cholangiocarcinoma patients following surgical resection: Adjuvant therapy is a favorable prognostic factor. Mol Clin Oncol 2014;2:1069-75. [PMID: 25279199 DOI: 10.3892/mco.2014.377] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
34 Popescu I, Dumitrascu T. Curative-intent surgery for hilar cholangiocarcinoma: prognostic factors for clinical decision making. Langenbecks Arch Surg 2014;399:693-705. [PMID: 24841192 DOI: 10.1007/s00423-014-1210-x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 4.0] [Reference Citation Analysis]
35 Serrablo A, Tejedor L. Outcome of surgical resection in Klatskin tumors. World J Gastrointest Oncol 2013; 5(7): 147-158 [PMID: 23919109 DOI: 10.4251/wjgo.v5.i7.147] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
36 Dumitrascu T, Chirita D, Ionescu M, Popescu I. Resection for hilar cholangiocarcinoma: analysis of prognostic factors and the impact of systemic inflammation on long-term outcome. J Gastrointest Surg 2013;17:913-24. [PMID: 23319395 DOI: 10.1007/s11605-013-2144-2] [Cited by in Crossref: 57] [Cited by in F6Publishing: 60] [Article Influence: 5.7] [Reference Citation Analysis]
37 Rerknimitr R, Angsuwatcharakon P, Ratanachu-ek T, Khor CJ, Ponnudurai R, Moon JH, Seo DW, Pantongrag-Brown L, Sangchan A, Pisespongsa P, Akaraviputh T, Reddy ND, Maydeo A, Itoi T, Pausawasdi N, Punamiya S, Attasaranya S, Devereaux B, Ramchandani M, Goh KL; Asia-Pacific Working Group on Hepatobiliary Cancers. Asia-Pacific consensus recommendations for endoscopic and interventional management of hilar cholangiocarcinoma. J Gastroenterol Hepatol 2013;28:593-607. [PMID: 23350673 DOI: 10.1111/jgh.12128] [Cited by in Crossref: 157] [Cited by in F6Publishing: 152] [Article Influence: 15.7] [Reference Citation Analysis]
38 Cereda S, Belli C, Reni M. Adjuvant treatment in biliary tract cancer: To treat or not to treat? World J Gastroenterol 2012; 18(21): 2591-2596 [PMID: 22690066 DOI: 10.3748/wjg.v18.i21.2591] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]